FDA approves first ever drug specifically for postpartum depression

The drug, called brexanolone (brand name Zulresso), needs to be given in a health care facility under medical supervision and is delivered intravenously over the course of 60 hours (2.5 days). It is fast acting. Women feel better as early as 48 into treatment and maintain benefits for at least 30 days. The company has an oral version of the drug in the pipeline.